|
Shield Therapeutics PLC on Thursday reported a narrowing of its half-year loss, bolstered by US sales and milestone payments globally, as it backed its full-year cash flow guidance. The Newcastle, England-based commercial-stage pharmaceutical company said its pretax loss narrowed $9.4 million in the six months that ended June 30, from $15.5 million a year earlier. Shares in Shield Therapeutics were 6.9% higher at 7.16 pence on Thursday afternoon in London. Helping its loss narrow was a 77% advance in revenue to $21.4 million from $12.1 million, with Shield Therapeutics benefitting from increased US sales of Accrufer. Sales in the region climbed 75% to $19.2 million from $11.0 million. Accrufer is the company’s oral treatment for patients with iron deficiency with or without anaemia. Outside of the US, the company reported $2.2 million in milestones and royalties revenue from partners in Europe, Canada and Japan, doubling from the year before. A reduction in operating costs further supported the bottom line, down 17% to $15.6 million from $18.8 million. Cash and cash equivalents improved to $10.8 million at June 30, up from $6.5 million at December 31. Looking ahead, the company backed its cash flow guidance for the full-year, with it expecting to turn cash flow positive by the end of the year. ‘We are encouraged by Accrufer’s strong performance in H1 2025, following the increasing market adoption of Accrufer, which further validates its substantial potential. Operationally, we made significant progress globally, including the launch of Accrufer in Canada, a new licensing agreement in Japan, and the successful completion of a key Phase 3 study in China. We also submitted regulatory filings for paediatric use in both Europe and the US following positive trial results,’ said Chief Executive Anders Lundstrom ‘These results reflect the growing demand for Accrufer and the successful execution of our strategy to expand access to patients worldwide,’ continued Lundstrom. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
